These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 1453772

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Optimizing therapy for acute myeloid leukemia based on differences in intracellular metabolism of cytosine arabinoside between leukemic blasts and normal mononuclear blood cells.
    Hiddemann W, Schleyer E, Unterhalt M, Kern W, Büchner T.
    Ther Drug Monit; 1996 Aug; 18(4):341-9. PubMed ID: 8857548
    [Abstract] [Full Text] [Related]

  • 3. Cytosine arabinoside transport and metabolism in acute leukemias and T cell lymphoblastic lymphoma.
    Wiley JS, Taupin J, Jamieson GP, Snook M, Sawyer WH, Finch LR.
    J Clin Invest; 1985 Feb; 75(2):632-42. PubMed ID: 3871794
    [Abstract] [Full Text] [Related]

  • 4. Modulation of intracellular metabolism of cytosine arabinoside in acute myeloid leukemia by granulocyte-macrophage colony-stimulating factor.
    Reuter C, Auf der Landwehr U, Schleyer E, Zühlsdorf M, Ameling C, Rolf C, Wörmann B, Büchner T, Hiddemann W.
    Leukemia; 1994 Feb; 8(2):217-25. PubMed ID: 8309245
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Leukaemic blasts differ from normal bone marrow mononuclear cells and CD34+ haemopoietic stem cells in their metabolism of cytosine arabinoside.
    Braess J, Wegendt C, Feuring-Buske M, Riggert J, Kern W, Hiddemann W, Schleyer E.
    Br J Haematol; 1999 May; 105(2):388-93. PubMed ID: 10233409
    [Abstract] [Full Text] [Related]

  • 7. [Intracellular retention of cytarabine-triphosphate (Ara-CTP) in blasts of children with acute lymphoblastic leukemia. Correlation with clinical course parameters].
    Schiller M, Hohenlöchter B, Schulze-Westhoff P, Zimmermann M, Ritter J, Jürgens H, Boos J.
    Klin Padiatr; 1996 May; 208(4):151-9. PubMed ID: 8926681
    [Abstract] [Full Text] [Related]

  • 8. Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy.
    Plunkett W, Liliemark JO, Adams TM, Nowak B, Estey E, Kantarjian H, Keating MJ.
    Cancer Res; 1987 Jun 01; 47(11):3005-11. PubMed ID: 3471322
    [Abstract] [Full Text] [Related]

  • 9. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
    Gandhi V, Estey E, Du M, Keating MJ, Plunkett W.
    Clin Cancer Res; 1997 Sep 01; 3(9):1539-45. PubMed ID: 9815841
    [Abstract] [Full Text] [Related]

  • 10. Abrogation of the prognostic significance of low leukemic cell retention of cytosine arabinoside triphosphate by intensification of therapy and by alteration in the dose and schedule of administration of cytosine arabinoside.
    Preisler HD, Rustum YM, Azarnia N, Priore R.
    Cancer Chemother Pharmacol; 1987 Sep 01; 19(1):69-74. PubMed ID: 3815728
    [Abstract] [Full Text] [Related]

  • 11. Complementary antineoplastic activity of the cytosine nucleoside analogues troxacitabine (Troxatyl) and cytarabine in human leukemia cells.
    Bouffard DY, Jolivet J, Leblond L, Hamelin B, Ouellet F, Barbeau S, Richard A, Gourdeau H.
    Cancer Chemother Pharmacol; 2003 Dec 01; 52(6):497-506. PubMed ID: 12955470
    [Abstract] [Full Text] [Related]

  • 12. Relationship of 1-beta-D-arabinofuranosylcytosine in plasma to 1-beta-D-arabinofuranosylcytosine 5'-triphosphate levels in leukemic cells during treatment with high-dose 1-beta-D-arabinofuranosylcytosine.
    Liliemark JO, Plunkett W, Dixon DO.
    Cancer Res; 1985 Nov 01; 45(11 Pt 2):5952-7. PubMed ID: 4053067
    [Abstract] [Full Text] [Related]

  • 13. Oral cytarabine ocfosfate in acute myeloid leukemia and non-Hodgkin's lymphoma--phase I/II studies and pharmacokinetics.
    Braess J, Freund M, Hanauske A, Heil G, Kaufmann C, Kern W, Schüssler M, Hiddemann W, Schleyer E.
    Leukemia; 1998 Oct 01; 12(10):1618-26. PubMed ID: 9766508
    [Abstract] [Full Text] [Related]

  • 14. Long intracellular retention of 4'-thio-arabinofuranosylcytosine 5'-triphosphate as a critical factor for the anti-solid tumor activity of 4'-thio-arabinofuranosylcytosine.
    Someya H, Waud WR, Parker WB.
    Cancer Chemother Pharmacol; 2006 Jun 01; 57(6):772-80. PubMed ID: 16180016
    [Abstract] [Full Text] [Related]

  • 15. Successful modulation of high-dose cytosine arabinoside metabolism in acute myeloid leukaemia by haematopoietic growth factors: no effect of ribonucleotide reductase inhibitors fludarabine and gemcitabine.
    Braess J, Wegendt C, Jahns-Streubel G, Kern W, Keye S, Unterhalt M, Schleyer E, Hiddemann W.
    Br J Haematol; 2000 May 01; 109(2):388-95. PubMed ID: 10848830
    [Abstract] [Full Text] [Related]

  • 16. AraU accumulation in patients with renal insufficiency as a potential mechanism for cytarabine neurotoxicity.
    Lindner LH, Ostermann H, Hiddemann W, Kiani A, Würfel M, Illmer T, Karsch C, Platzbecker U, Ehninger G, Schleyer E.
    Int J Hematol; 2008 Nov 01; 88(4):381-386. PubMed ID: 18836794
    [Abstract] [Full Text] [Related]

  • 17. Intracellular retention of cytosine arabinoside triphosphate in blast cells from children with acute myelogenous and lymphoblastic leukemia.
    Boos J, Hohenlöchter B, Schulze-Westhoff P, Schiller M, Zimmermann M, Creutzig U, Ritter J, Jurgens H.
    Med Pediatr Oncol; 1996 Jun 01; 26(6):397-404. PubMed ID: 8614376
    [Abstract] [Full Text] [Related]

  • 18. High-dose versus intermediate-dose cytosine arabinoside in combination with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia--preliminary clinical and pharmacological data of a randomized comparison.
    Hiddemann W, Schleyer E, Uhrmeister C, Aul CH, Maschmeyer G, Heinecke A, Büchner T.
    Cancer Treat Rev; 1990 Sep 01; 17(2-3):279-85. PubMed ID: 2272043
    [Abstract] [Full Text] [Related]

  • 19. Transport and metabolism of 1-beta-D-arabinofuranosylcytosine in human ovarian adenocarcinoma cells.
    Jamieson GP, Snook MB, Bradley TR, Bertoncello I, Wiley JS.
    Cancer Res; 1989 Jan 15; 49(2):309-13. PubMed ID: 2910450
    [Abstract] [Full Text] [Related]

  • 20. Degradation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in human leukemic myeloblasts and lymphoblasts.
    Jamieson GP, Finch LR, Snook M, Wiley JS.
    Cancer Res; 1987 Jun 15; 47(12):3130-5. PubMed ID: 3472653
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.